Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Biosense Webster, Inc. revealed marketing clearance from the U.S. Food and Drug Administration for its CARTO 3 System for treating cardiac arrhythmias

CARTO 3 System is a three-dimensional imaging technology for use by electrophysiologists in treating cardiac arrhythmias, commonly known as irregular heart rhythms.

An estimated 20 million people in the U.S. suffer from some sort of arrhythmia. Atrial fibrillation is the most prevalent cardiac arrhythmia, affecting between 2.3 to 5.6 million adults in the U.S. alone and is the leading cause of stroke among people 65 years and older.

"The CARTO 3 System is the world's most sophisticated 3D mapping platform on the market today," said Shlomi Nachman, president of Biosense.

The three unique features offered by the CARTO 3 System are Advanced Catheter Location (ACL) Technology, Fast Anatomical Mapping, and Connection of Choice. Advanced Catheter Location Technology is a hybrid technology that allows for accurate catheter tip and curve visualization without spatial distortion.

Fast Anatomical Mapping is a technology that quickly and accurately creates high-resolution, CT-like maps as quickly as an EP can move his or her catheter throughout the cardiac chamber. Connection of Choice is a streamlined work flow feature set featuring a central connection point for all catheters and equipment. These three features work in tandem to enhance a physician's ability to treat an array of simple and complex cardiac arrhythmias, a statement said.

Source: Biosense Webster, Inc.

You can also discuss more about Cardiology and related topics in our Cardiology Group.